Array BioPharma announced positive results from the Phase III BEACON CRC trial evaluating a triple combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovia (binimetinib), and the anti-EGFR antibody Erbitux (cetuximab) in patients with advanced BRAFV600E-mutant metastatic colorectal cancer after one or two lines of therapy.
Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.
Pfizer Spins Off Four of Its Best Drug Candidates Into a Startup With $103 Million
Big Pharma, Biotech, FAAH Inhibitors, Gamma-Secretase Inhibitors, Genetic Diseases, Hereditary Xerocytosis, MEK Inhibitors, Neurofibromatosis, Post-Traumatic Stress Disorder, Product Pipelines, Rare Diseases, Rare Disorders, Red Blood Cell, Science, Startups, TumorsPfizer launched a six-person biotech startup, SpringWorks Therapeutics, with a $103 million Series A financing. Joining Pfizer in funding the company was Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed and LifeArc, formerly known as MRC Technology.
Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.
Array BioPharma And Pierre Fabre Announce Development And Commercialization Collaboration For Two Novel Oncology Products, Binimetinib And Encorafenib
Asia, Biopharma, BRAF Inhibitors, Canada, Clinical Trials, Collaboration, Collaborations, Europe, Health, Israel, Japan, Korea, Latin America, MEK Inhibitors, Melanoma, Ovarian Cancer, R&D, Royalties– Array to receive a $30 million up-front payment and up to $425 million in additional development and commercialization milestones, as well as robust double-digit royalties on future sales – – Array retains full commercialization rights to binimetinib and encorafenib in United States, Canada, Japan and Korea – -NEMO Phase 3 trial remains on-track for […]
Amgen wins EU green light for first virus-based cancer drug
Approvals, Approvals, BRAF V600 Inhibitors, BRAF V600 inhibitors, Cancer Cells, EMA, FDA, FDA/Regulatory, Health, Herpes, Herpes Simplex Virus, Immune Response, Immunotherapies, Immunotherapy, M&A, M&A, MEK Inhibitors, MEK Inhibitors, Melanoma, New Drug ApprovalsA first-in-class drug from Amgen based on a tumor-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months. The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness. The European […]